Owlstone Medical raises $58m in Series D round
The proceeds will be used to enhance the Breath Biopsy platform and commercialise certain tests.

The proceeds will be used to enhance the Breath Biopsy platform and commercialise certain tests.
The study, referred to as the COMMAND trial, will include six severely paralysed patients.
Companies have reason to be sceptical about investing in Asia in general and in China in particular. But Asia investment…
Thank you for subscribing to Medical Device Network